Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2018 08:00 ET | Source: Immutep Limited

New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit

SYDNEY, Australia, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial is...
November 12, 2018 08:00 ET | Source: Immutep Limited

Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

SYDNEY, Australia, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
November 01, 2018 08:00 ET | Source: Immutep Limited

Operational Update

Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patientsAIPAC Phase IIb recruitment reaches 155 patients or more than 68%...
October 24, 2018 08:00 ET | Source: Immutep Limited

Immutep Announces Data Presentations at Upcoming Industry Conferences

SYDNEY, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
October 02, 2018 08:00 ET | Source: Immutep Limited

Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

SYDNEY, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
September 26, 2018 08:00 ET | Source: Immutep Limited

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

SYDNEY, Australia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
September 24, 2018 08:00 ET | Source: Immutep Limited

Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer

SYDNEY, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce that it has entered into a clinical trial...
September 03, 2018 08:00 ET | Source: Immutep Limited

Progress Towards Clinical Development of IMP761 – a LAG-3 Agonist Antibody

SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for...
August 21, 2018 04:44 ET | Source: Immutep Limited

Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government

SYDNEY, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
August 16, 2018 08:00 ET | Source: Immutep Limited

Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference

SYDNEY, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...